VERACYTE INC (VCYT)

Company Profile

Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The company is headquartered in South San Francisco, California and currently employs 815 full-time employees. The company went IPO on 2013-10-30. The firm enables clinicians with insights they need to guide and assure patients. The firm offers tests for thyroid cancer (Afirma), prostate cancer (Decipher Prostate), breast cancer (Prosigna), interstitial lung diseases (Envisia), and bladder cancer (Decipher Bladder). Its Percepta Nasal Swab test is being run in its Clinical Laboratory Improvement Amendments (CLIA) lab in support of clinical studies and its tests for kidney cancer and lymphoma are in development, the latter as a companion diagnostic. Its products consist of the Prosigna breast cancer assay, the nCounter Analysis System, related diagnostic kits, and services. In the United States, it offers laboratory developed tests (LDTs), through its CLIA labs in South San Francisco and San Diego, California, supported by its cytopathology know-how in Austin, Texas. The firm also offers whole-genome MRD platform that enable it in early cancer diagnosis and risk assessment.

Company Info

VERACYTE INC

6000 Shoreline Court, Suite 300

South San Francisco CALIFORNIA 94080

P: 16502436300

CEO: Bonnie H. Anderson

Employees: 815

Website: https://www.veracyte.com/